Latest Diabetes mellitus type 1 Stories

Degenerative changes to the area of the spinal disc that absorbs most of shock felt with compression, known as the nucleus pulposus, has been demonstrated and reversed in a diabetic mouse model, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai. New York, NY (PRWEB) May 17, 2013 Degenerative changes to the area of the spinal disc that absorbs most of the shock felt with compression, known as the nucleus pulposus, has been demonstrated and reversed...

Contest raised over $53,000 for organizations committed to diabetes awareness, education and support PRINCETON, N.J., May 16, 2013 /PRNewswire/ -- Novo Nordisk, the world leader in diabetes care, along with author, restaurateur and Food Network star Paula Deen, have selected six winners for their positive approach to diabetes management in the Seeing Diabetes in a New Light(TM) contest. Participants were asked to share what they or their loved one has done to manage the disease, and...

B. Riley & Co. and The Sugar Ray Leonard Foundation present The 4th Annual "Big Fighters, Big Cause" Charity Fight Night to benefit The Sugar Ray Leonard Foundation in its support for Juvenile Diabetes Research and The Wounded Warrior Project. This prestigious invitation-only Red Carpet event will take place at The Santa Monica Pier on May 21, 2013. Los Angeles, CA (PRWEB) May 14, 2013 B. Riley & Co. and The Sugar Ray Leonard Foundation present The 4th Annual "Big...

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial. LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2). The pioneer phase of the study was designed to gain...

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2013. "In the first quarter of 2013, we continued to progress our clinical pipeline on multiple fronts. Most...

The new position will oversee JDRF's efforts to bridge research and development of life-changing therapies for type 1 diabetes NEW YORK, May 8, 2013 /PRNewswire-USNewswire/ -- JDRF announced today its new executive vice president of research and advocacy, David E. Wheadon, M.D. Dr. Wheadon brings 26 years of experience as a highly effective leader in drug development and translational research, regulatory and medical affairs, and patient advocacy. In this new position, he will work...

Some of the earliest results from The Environmental Determinants of Diabetes in The Young (TEDDY) study - a major Europe-USA consortium exploring the causes of type 1 diabetes in children – has found no evidence for viral infection as a cause of the rapid-onset form of the condition. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) and is by Professor Anette-Gabriele Ziegler of the German Research Centre for Environmental Health...

Taking Diabetes to Heart Program Helps People Make Small but Important Lifestyle Changes WHITEHOUSE STATION, N.J., May 7, 2013 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced its partnership with celebrity chef Art Smith on Taking Diabetes to Heart, an educational program to help people living with type 2 diabetes better manage the disease. Smith, who lives with type 2 diabetes, will be traveling the country "cooking up" some of...

SALEM, N.H., May 7, 2013 /PRNewswire/ -- Enterasys Networks, a Siemens Enterprise Communications Company based in Salem, NH, will be supporting The American Diabetes Association's movement to Stop Diabetes® by having a team ride in the annual Tour de Cure(®). The cycling event is happening on Sunday, May 19, 2013 at the Topsfield Fairgrounds in Topsfield, MA to help raise funds to change the future of diabetes and help stop this devastating disease. The team started because of...

Retrospective pooled analyses evaluated linagliptin treatment in American Hispanic/Latino people with type 2 diabetes, as well as in people living with type 2 diabetes for at least 10 years RIDGEFIELD, Conn. and INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented at the...